Loading anticancer drugs into HDL as well as LDL has little affect on properties of complexes and enhances cytotoxicity to human carcinoma cells.

Low density lipoprotein (LDL) has been found to represent a suitable carrier for cytotoxic drugs that may target them to cancer. This study investigated whether very low density lipoprotein (VLDL), LDL and high density lipoprotein (HDL) can be used to effectively incorporate four cytotoxic drugs, 5-fluorouracil (5-FU), 5-iododeoxyuridine (IUdR), doxorubicin (Dox) and vindesine; characterized the complexes; and examined the effect of incorporation on drug cytotoxicity against HeLa cervical and MCF-7 breast carcinoma cells. Significant drug loading was achieved into all three classes of lipoproteins, consistent with the sizes and hydrophobicity of the drugs. The relative loading efficiency was found to be vindesine>IUdR>Dox>5-FU for all three classes of lipoproteins. As shown by electron microscopy (EM), drug incorporation did not affect the size or morphology of the lipoproteins. Differential scanning calorimetry (DSC) showed that drug loading did not significantly change the thermal transition temperature of core lipids in the lipoproteins. The transition enthalpy was changed only for LDL-Dox and LDL-vindesine. The drugs remained stable in the lipoproteins as determined by high performance liquid chromatography (HPLC). EM, DSC and HPLC data suggest that drugs were incorporated into lipoproteins without disrupting their integrity and drugs remained in their stable forms inside lipoproteins. Compared with free drugs in cytotoxicity assays, the IC(50) values of LDL- and HDL-drug complexes were significantly lower (2.4- to 8.6-fold for LDL complexes and 2.5- to 23-fold for HDL complexes). All free or lipoprotein-bound drug formulations were comparably more cytotoxic against MCF-7 than HeLa cells. Upregulating the lipoprotein receptors enhanced, and downregulating them inhibited, the cytotoxicity, indicating the mechanistic involvement of lipoprotein receptor pathways. Complexes of all four drugs with VLDL, in contrast to LDL and HDL, had the same cytotoxicity as the four corresponding free drugs. Our results suggest that further studies are required of the potential of HDL to be a cancer targeting drug carrier.

[1]  H. Hauser,et al.  Structural organization of free and esterified cholesterol in human high density lipoproteins. A 100.6 MHz 13C NMR study. , 1979, Biochimica et biophysica acta.

[2]  E. Simpson,et al.  Cholesterol metabolism in cancer cells in monolayer culture. III. Low‐density lipoprotein metabolism , 1981, International journal of cancer.

[3]  T. Laudański,et al.  Treatment of cancer patients with a low-density-lipoprotein delivery vehicle containing a cytotoxic drug , 2004, Cancer Chemotherapy and Pharmacology.

[4]  Y. Barenholz,et al.  Targeted Delivery of Doxorubicin via Sterically Stabilized Immunoliposomes: Pharmacokinetics and Biodistribution in Tumor-bearing Mice , 1996, Pharmaceutical Research.

[5]  O. Chassany,et al.  Comparative serum protein binding of anthracycline derivatives , 1996, Cancer Chemotherapy and Pharmacology.

[6]  G. Lopez-Berestein,et al.  Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. , 1994, Journal of pharmaceutical sciences.

[7]  J. Fruchart,et al.  Interaction of LpB, LpB:E, LpB:C-III, and LpB:C-III:E lipoproteins with the low density lipoprotein receptor of HeLa cells. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[8]  E. Simpson,et al.  Low-density lipoprotein as a potential vehicle for chemotherapeutic agents and radionucleotides in the management of gynecologic neoplasms. , 1981, American journal of obstetrics and gynecology.

[9]  John W. Park,et al.  Development of anti-p185HER2 immunoliposomes for cancer therapy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  M. Bally,et al.  A two-step targeting approach for delivery of doxorubicin-loaded liposomes to tumour cells in vivo , 2004, Cancer Chemotherapy and Pharmacology.

[11]  P. Denéfle,et al.  Somatic gene transfer of human ApoA-I inhibits atherosclerosis progression in mouse models. , 1999, Circulation.

[12]  J. K. Kruijt,et al.  Selective liver targeting of antivirals by recombinant chylomicrons — a new therapeutic approach to hepatitis B , 1995, Nature Medicine.

[13]  H. Robenek,et al.  Differences in the mechanisms of uptake and endocytosis of small and large chylomicron remnants by rat liver. , 1996, Hepatology.

[14]  B. Yung,et al.  Identification of high‐density lipoprotein in serum to determine anti‐cancer efficacy of doxorubicin in HeLa cells , 1992, International journal of cancer.

[15]  D. Pc,et al.  LDL-mediated drug targeting. , 1990 .

[16]  D. Steinberg,et al.  Uptake of high-density lipoprotein-associated apoprotein A-I and cholesterol esters by 16 tissues of the rat in vivo and by adrenal cells and hepatocytes in vitro. , 1985, The Journal of biological chemistry.

[17]  A. Pater,et al.  Incorporation of an (125)I-labeled hexa-iodinated diglyceride analog into low-density lipoprotein and high specific uptake by cells of cervical carcinoma cell lines. , 1999, Radiation research.

[18]  V. Richardson,et al.  Comparison of tetrazolium colorimetric and [3H]-uridine assays for in vitro chemosensitivity testing , 2004, Cancer Chemotherapy and Pharmacology.

[19]  O. Glatter,et al.  Lipoprotein-associated α-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells , 2000 .

[20]  D. Scraba,et al.  Prevention of phospholipase‐C induced aggregation of low density lipoprotein by amphipathic apolipoproteins , 1993, FEBS letters.

[21]  A. Kader,et al.  Drug targeting using low density lipoprotein (LDL): physicochemical factors affecting drug loading into LDL particles. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[22]  S. Vitols,et al.  Low Density Lipoprotein as a Carrier of Cytostatics in Cancer Chemotherapy: Study of Stability of Drug-carrier Complexes in Blood , 2000, Journal of drug targeting.

[23]  T. V. van Berkel,et al.  Synthesis of the dioleoyl derivative of iododeoxyuridine and its incorporation into reconstituted high density lipoprotein particles. , 1994, Biochemistry.

[24]  K. Wasan,et al.  Differences in Lipoprotein Concentration and Composition Modify the Plasma Distribution of Free and Liposomal Annamycin , 1996, Pharmaceutical Research.

[25]  A. Lehninger.  Principles of Biochemistry , 1984 .

[26]  R. Stocker,et al.  Greater selective uptake by Hep G2 cells of high-density lipoprotein cholesteryl ester hydroperoxides than of unoxidized cholesteryl esters. , 1993, The Biochemical journal.

[27]  A. Miyauchi,et al.  Evidence for a potential role for HDL as an important source of cholesterol in human adrenocortical tumors via the CLA-1 pathway. , 1999, Endocrine journal.

[28]  L. Schook,et al.  Delivery of Lipophilic Drugs Using Lipoproteins a , 1987, Annals of the New York Academy of Sciences.

[29]  T. Marlovits,et al.  Very-Low-Density Lipoprotein Receptor Fragment Shed from HeLa Cells Inhibits Human Rhinovirus Infection , 1998, Journal of Virology.

[30]  B. Lundberg.  Assembly of prednimustine low-density-lipoprotein complexes and their cytotoxic activity in tissue culture , 2004, Cancer Chemotherapy and Pharmacology.

[31]  V. Schumaker,et al.  [6] Sequential flotation ultracentrifugation , 1986 .

[32]  S. Yanovich,et al.  Characteristics of uptake and cytotoxicity of a low-density lipoprotein-daunomycin complex in P388 leukemic cells. , 1984, Cancer research.

[33]  C. Sing,et al.  Apolipoprotein E polymorphism and atherosclerosis. , 1988, Arteriosclerosis.

[34]  T. J. Berkel,et al.  Drug targeting: application of endogenous carriers for site-specific delivery of drugs , 1993 .

[35]  R. Firestone,et al.  Low-density lipoprotein as a vehicle for targeting antitumor compounds to cancer cells. , 1994, Bioconjugate chemistry.

[36]  K. Sasagawa,et al.  Plasma lipoproteins as targeting carriers to tumour tissues after administraion of a lipophilic agent to mice , 1995, Biopharmaceutics & drug disposition.

[37]  Plasma stability and cytotoxicity of lipophilic daunorubicin derivatives incorporated into low density lipoproteins. , 2000, European journal of medicinal chemistry.

[38]  T. Willnow.  The low-density lipoprotein receptor gene family: multiple roles in lipid metabolism , 1999, Journal of Molecular Medicine.

[39]  J. Breslow,et al.  Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  S. Penco,et al.  Chemical and biological characterization of 4'-iodo-4'-deoxydoxorubicin. , 1987, Cancer research.

[41]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[42]  M Lemaire,et al.  Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood , 1982, The Journal of pharmacy and pharmacology.